CMP (Rs) 326 Upside/ (Downside) (%) 24. Market Cap. (Rs bn) 21.7 Free Float (%) 42.0 Shares O/S (mn) 67

Similar documents
CMP* (Rs) 346 Upside/ (Downside) (%) 17. Market Cap. (Rs bn) 23 Free Float (%) 42.0 Shares O/S (mn) 67

CMP* (Rs) 208 Upside/ (Downside) (%) 18. Market Cap. (Rs bn) Free Float (%) 65.6 Shares O/S (mn) 630

CMP* (Rs) 417 Upside/ (Downside) (%) 46 Bloomberg Ticker. SUNP IN Market Cap. (Rs bn) 1,001 Free Float (%) 46 Shares O/S (mn) 2399

CMP (Rs) 775 Upside/ (Downside) (%) (1.4) Market Cap. (Rs bn) 11.4 Free Float (%) 35.0 Shares O/S (mn) 14.7

CMP* (Rs) 242 Upside/ (Downside) (%) 2. Market Cap. (Rs bn) 157 Free Float (%) 65.6 Shares O/S (mn) 630

CMP* (Rs) 336 Upside/ (Downside) (%) 21 Bloomberg Ticker. MOIL IN Market Cap. (Rs bn) 45 Free Float (%) 24 Shares O/S (mn) 133

CMP* (Rs) 166 Upside/ (Downside) (%) 28 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,361 Free Float (%) 37.7 Shares O/S (mn) 8,245

CMP* (Rs) 840 Upside/ (Downside) (%) (2.4) Bloomberg Ticker Market Cap. (Rs bn) 379 Free Float (%) 53 Shares O/S (mn) 451.6

Nestlé India Outlook Hazy; Valuations Prohibitive

CMP* (Rs) 1,458 Upside/ (Downside) (%) 10 Bloomberg Ticker. ABB IN Market Cap. (Rs bn) 309 Free Float (%) 25 Shares O/S (mn) 212

BUY NCC. An Ordinary Quarterly Performance; Maintain BUY. Target Price: Rs98. Institutional Equity Research. 4QFY17 Result Update May 24, 2017

CMP* (Rs) 203 Upside/ (Downside) (%) 23. Market Cap. (Rs bn) 116 Free Float (%) 61 Shares O/S (mn) 572

HOLD ACC. Strong Performance on Better Volume and Firm Realizations. Target Price: Rs1,640. Institutional Equity Research

CMP* (Rs) 205 Upside/ (Downside) (%) 12 Bloomberg Ticker. NACO IN Market Cap. (Rs bn) 29 Free Float (%) 27 Shares O/S (mn) 143

Titan Company BUY. Back to Value Zone Validate Rating Upgrade. Institutional Equity Research. November 05, Target Price Rs428.

HOLD. Nestle. Good Performance Irrespective of GST Pangs. Target Price: Rs6,624. Institutional Equity Research. 2QCY17 Result Update July 27,2017

CMP* (Rs) 161 Upside/ (Downside) (%) 19 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,329 Free Float (%) 30.3 Shares O/S (mn) 8,245

CMP* (Rs) 1,464 Upside/ (Downside) (%) 10. Market Cap. (Rs bn) 91 Free Float (%) 55 Shares O/S (mn) 62

CMP* (Rs) 263 Upside/ (Downside) (%) 7.3. Market Cap. (Rs bn) 635 Free Float (%) 59 Shares O/S (mn) 2,417

CMP* (Rs) 172 Upside/ (Downside) (%) 11.6 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,414 Free Float (%) 30.3 Shares O/S (mn) 8,245

CMP* (Rs) 360 Upside/ (Downside) (%) 25. Market Cap. (Rs bn) 38 Free Float (%) 76 Shares O/S (mn) 104.5

BUY NTPC. Higher Regulated Equity to Aid Profitability; Maintain BUY. Target Price: Rs192. Institutional Equity Research

BUY CDSL. Strong Operating Performance; Maintain BUY. Target Price: Rs435. Institutional Equity Research. 2QFY18 Result Update October 31, 2017

CMP* (Rs) 1,033 Upside/ (Downside) (%) (0.3) Bloomberg Ticker Market Cap. (Rs bn) 467 Free Float (%) 53 Shares O/S (mn) 452

CMP (Rs) 249 Upside/ (Downside) (%) Market Cap. (Rs bn) 25.5 Free Float (%) 29.7 Shares O/S (mn) 102.3

CMP (Rs) 702 Upside/ (Downside) (%) 42 Bloomberg Ticker. JKCE IN Market Cap. (Rs bn) 54 Free Float (%) 42 Shares O/S (mn) 77.3

KNR Constructions Robust Performance on Execution Ramp-up

CMP* (Rs) 1,424 Upside/ (Downside) (%) 19 Bloomberg Ticker Market Cap. (Rs bn) 268 Free Float (%) 46 Shares O/S (mn) 188

CMP* (Rs) 237 Upside/ (Downside) (%) 29 Bloomberg Ticker. APTY IN Market Cap. (Rs bn) 136 Free Float (%) 55.9 Shares O/S (mn) 509

BUY. DCB Bank. Improving Capital Consumption to Aid Returns; Maintain BUY. Target Price: Rs202. Institutional Equity Research

CMP (Rs) 133 Upside/ (Downside) (%) 35 Bloomberg Ticker. ICEM IN Market Cap. (Rs bn) 41 Free Float (%) 71.6 Shares O/S (mn) 308.1

CMP* (Rs) 198 Upside/ (Downside) (%) 12. Market Cap. (Rs bn) 61 Free Float (%) 84 Shares O/S (mn) 308

CMP* (Rs) 189 Upside/ (Downside) (%) (1) Bloomberg Ticker PNB IN Market Cap. (Rs bn) 402 Free Float (%) 38 Shares O/S (mn) 2,128

CMP* (Rs) 289 Upside/ (Downside) (%) 18. Market Cap. (Rs bn) 30 Free Float (%) 69 Shares O/S (mn) 105

CMP* (Rs) 145 Upside/ (Downside) (%) 32 Bloomberg Ticker BOB IN Market Cap. (Rs bn) 384 Free Float (%) 36 Shares O/S (mn) 2,646

Aurobindo Pharma. Institutional Equity Research. Sector - Pharmaceuticals. RSec TradEdge India. March 02, 2017

CMP (Rs) 166 Upside/ (Downside) (%) (1) Bloomberg Ticker Market Cap. (Rs bn) 125 Free Float (%) 37 Shares O/S (mn) 726

Sonata Software HOLD. Unimpressive Show; IITS Revenue Disappoints. Institutional Equity Research. February 06, Target Price Rs190.

Jubilant FoodWorks. Institutional Equity Research. Sector - FMCG. RSec TradEdge India. January 17, 2017

CMP* (Rs) 301 Upside/ (Downside) (%) 25. Market Cap. (Rs bn) 19.6 Free Float (%) 26 Shares O/S (mn) 65

KEC International. Recovering from a weak phase. Institutional Equity Research. Order inflow traction remains intact

Power Mech Projects. Institutional Equities. 2QFY19 Result Update BUY. Strong Order Book Drives Robust Execution

Gillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance

Key estimate revision. Financial summary. Year FY14 391,088 45,198 34, FY15E 354,262 35,426 23,

BUY. Efforts on cost cutting paying off RAMCO CEMENTS. Target Price: Rs 435. Key highlights. Key drivers FY15 FY16E FY17E

Amber Enterprises India Ltd

Robust results, TLT margins improved profitability.

Balkrishna Industries

HOLD. Deleveraging story playing out RAMCO CEMENTS. Target Price: Rs 503. Q4 performance

Ahluwalia Contracts (India)

Kalpataru Power. Rating: Target price: EPS: Rating CMP. Target BUY. Rs Rs.256

Transport Corporation of India Ltd.

Colgate-Palmolive (India)

Transport Corporation of India Ltd.

Power Mech Projects. Institutional Equities. 2QFY18 Result Update BUY. Strong Business Scalability Likely; Retain Buy

Gillette India. Institutional Equities. 1QFY18 Result Update

TTK Prestige Ltd. Result Highlights. Revenue growth of 41% YoY, shows no slowdown yet. OPM at ~15.8%; in line with our estimate

Cummins India Ltd Bloomberg Code: KKC IN

ITC. Institutional Equities. 4QFY18 Result Update. Tracking Expectations ACCUMULATE. Sector: FMCG CMP: Rs286 Target Price: Rs290 Upside: 1%

Ahluwalia Contracts. Cautious optimism BUY RESULTS REVIEW 4QFY17 31 MAY Highlights of the quarter

Consolidated Sales (Cr) Growth EBITDA (Cr) Margin PAT Margin EPS (Rs) P/E RoE

Strides Arcolab. Inline 4Q, recent acquisitions to deepen asset growth. Institutional Equity Research. Strides Arcolab. Pharmaceuticals India

KEC International Ltd.

Visaka Industries Ltd

Inox Wind BUY. Performance Highlights. CMP Target Price `242 `286. 4QFY2016 Result Update Capital Goods. 3 year price chart

Adani Ports & SEZ Rating: Target price: EPS:

Ramco Cement. Rating: Target price: EPS: Rating CMP. Target BUY. Rs.415. Rs. 360

Institutional Equities

Simplex Infrastructures

MCX Ltd. Rating: Target price: EPS: Tepid volume growth continues. Target. Rating CMP. Rs. 1,080 SELL. Rs. 1,176

HCC BUY. Infrastructure April 10, QIP step in the right direction EVENT UPDATE. India Research. Bloomberg: HCC IN Reuters: HCNS.

Dr Reddy s Laboratories

BLS International Services

Key estimate revision. Financial summary. Year FY16E 29, % 3,583 2, FY17E 26, % 3,478 2,

Jamna Auto Industries

Techno Electric & Engineering Limited

Bharat Forge. Result Update. Q4FY13 Result Highlights. Valuation. No Respite in Sight May 29, Institutional Research 1

Key estimate revision. Financial summary. Year FY15 121, % 16, % FY16E 137, % 20,

Quick take. Ruchira Papers Ltd. BUY. Creating value through paper. Target Price. Investment Period 12 Months. 3 year daily price chart.

Blue Star Ltd BUY. Performance Update. CMP Target Price `703 `867. 1QFY2019 Result Update Cons. Durable. 3-year price chart.

Crompton Greaves Consumer Electricals

Fineotex Chemical Ltd

TTK Prestige. Channel-check takeaways Growth recovery pace sees moderation, competitive headwinds continue to prevail. Target CMP. Rating Rs.

Near-term pressure, but long-term outlook positive

HCL Technologies. Rating: Target price: EPS: Target CMP. Rating. Rs. 826 REDUCE. Rs.760

Garware Wall Ropes ACCUMULATE. Performance Highlights CMP. `550 Target Price `618. 2QFY2017 Result Update Textile. Investment Period 12 months

BHEL SELL RESULTS REVIEW 1QFY15 13 AUG CMP (as on 12 Aug 2014) Rs 224 Target Price Rs 188

Dalmia Bharat Enterprises

Healty cigarette-driven growth

EBITDA 5,076 3, , EBITDA

MCX Ltd. Rating: Target price: EPS: Is commodity option a game changer for MCX? - Unlikely. Target. Rating CMP. Rs. 1,080 SELL. Rs.

Hindustan Media Ventures

Sonata Software BUY. Laying the Platform for Growth. Institutional Equity Research. December 01, Target Price Rs185.

Initiating Coverage. Uflex Ltd.

BUY. At inflection point NTPC. Target Price: Rs 197. Key highlights. Financial summary (Standalone) Y/E March FY16 FY17 FY18E FY19E.

J. Kumar Infraprojects

ITC ACCUMULATE. Performance Highlights CMP. `257 Target Price `284. 3QFY2017 Result Update FMCG. Investment Period 12 Months

Timken India. Institutional Equities. 4QFY16 Result Update BUY. Margin Expansion Leads To Huge Growth In Profit; Retain Buy

Indian Oil Corporation

Mahindra & Mahindra Ltd.

Transcription:

Management Meet Update March 29, 2019 Market Cap. (Rs bn) 21.7 Free Float (%) 42.0 Shares O/S (mn) 67 Healthy Growth Visibility & Attractive Valuations Augur Well We recently visited (India) Ltd. (AHLU) to understand its current status of business and way forward. No Significant Revenue Loss Expected: Unlike Rs1.2bn revenue loss in 3QFY19 from projects in Bihar and Delhi/NCR, AHLU is unlikely to report any revenue loss in the current quarter, as issues pertaining to the National Green Tribunal (NGT) are sorted out and execution of those projects are underway now. Notably, around ~45% of its total projects are from Delhi/NCR and NGT s adverse order in various projects had impacted execution. Further, one CPWD project worth Rs2.6bn is still stuck due to tree cutting issues and pending decision from the Supreme Court, which is most likely to see change in scope of work. We expect AHLU to report >20% revenue growth in 4QFY19 and thus, the Company is likely to maintain its revenue growth guidance of 10% in FY19E. Share price (%) 1 mth 3 mth 12 mth Absolute performance 10.5 (0.2 ) (12.6) Relative to Nifty 3.8 (6.9) (26.4) Shareholding Pattern (%) Sep 18 Dec'18 Promoter 58.0 58.0 Public 42.0 42.0 1 Year Stock Price Performance 450 Order Book Surged Further: As AHLU received LoA for 3 projects aggregating to Rs10bn in Feb-Mar 19, its order book has surged to Rs64bn (including 3QFY19 execution), which is 3.7x of TTM revenue. Total order inflow for FY19 now stands at Rs45bn as against Rs13bn in FY18. Notably, there is no L1 position as of now and it is currently bidding projects worth Rs20bn and expects to add projects worth Rs20nbn in FY20E mainly from hospital, institutional, commercial and residential segments. Fixed Price Contracts Unlikely to Impact Margin: AHLU currently has 2 projects from NBCC aggregating worth Rs8bn, which are fixed price based. NBCC had awarded Charbagh railway station projects (Rs5.4bn) and auditorium work contract at Kolkata (Rs3.15bn) to AHLU as fixedprice contracts. However, as designing right in these projects are with AHLU and it has sufficiently built escalation provisioning while bidding, it does not expect any adverse impact in margin in a scenario of higher input cost. It expects EBITDA margin in 13% range, going forward. 400 350 300 250 200 Mar-18 Apr-18 May- Jun-18 Jul-18 Aug-18 Sep-18 Oct-18 Nov-18 Dec-18 Jan-19 Feb-19 Mar-19 Working Capital Cycle to Remain at Simailar Level: AHLU does not expect any meaningful improvement in its working capital cycle, which is currently around 60 days. However, with the likely realisation of amounts from arbitration award may aid the Company to see marginal improvement in its receivable days. Further, it has not witnessed any delay in payment from private residential segment despite liquidity crisis in the industry. Outlook & Valuation We maintain our positive stance on AHLU mainly on the back of: (1) asset light business model; (2) strong balance-sheet (D/E ratio at 0.05x); (3) best-in-class return ratios; and (4) no equity commitment unlike several other construction companies. Expecting AHLU s revenue and PAT to clock 17% and 20% CAGR, respectively over FY18-FY21E, we reiterate our recommendation on the stock with an unrevised Target Price of Rs405 (16x FY20 EPS). Key Financials (Rs mn) FY18 FY19E FY20E FY21E Sales 16,466 18,019 22,825 26,332 EBITDA 2,193 2,293 2,920 3,409 Net Profit 1,154 1,266 1,699 2,003 EPS (Rs) 17.2 18.9 25.4 29.9 DPS (Rs) 0 0.3 0.4 0.5 P/E (x) 18.9 17.2 12.8 10.9 P/B (x) 3.5 2.9 2.4 2.0 EV/EBITDA (x) 9.5 9.2 7.0 5.7 RoE (%) 20.4 18.4 20.4 19.8 Divi. Yield (%) 0.0 0.1 0.1 0.2 Source: Company, RSec Research Research Analyst: Binod Modi Contact: 022 3330 4626 Email: binod.modi@relianceada.com 1

Engineers Hiring Increases: As AHLU has witnessed a sizeable increase in its order inflow, hiring of engineers increased from annualised average of 70-80 to >100 and the trend is likely to continue for sometimes. Kota Project Leased out up to 70%; Divestment on the Cards: Kota project has been leased out its commercial spaces ~70%. Further, AHLU is still committed to exit the projects in the due course once it reaches 80-90% lease out mark in order to focus on core operation. Arbitration Award: The conclusion of Talkatora award (balance amount Rs130mn) is at final stage and the final hearing is expected in 1HFY20E. However, there is no significant progress in Emaar MGF arbitration award (Rs470mn), as the presiding judge is still not available. AHLU does not expect any amount to be written-off. Risks to the View ff Lower-than-expected order inflow due to delay in capex recovery. ff Any delay in project execution. 2

Profit & Loss Statement Net Sales 16,466 18,019 22,825 26,332 Total Expenditure 14,273 15,726 19,905 22,923 EBITDA 2,193 2,293 2,920 3,409 EBITDA Margin (%) 13.3 12.7 12.8 12.9 Financial Charges 251 178 131 113 Depreciation 256 271 300 358 Other Income 63 73 83 96 Profit before tax 1749 1917 2573 3034 Total Tax 594 651 874 1,031 % of PBT 34.0 34.0 34.0 34.0 Profit after tax 1,154 1,266 1,699 2,003 PAT Margin (%) 7.0 7.0 7.4 7.6 Adjusted EPS 17.23 18.89 25.36 29.90 Balance Sheet Shareholders Funds Share Capital 134 134 134 134 Reserves and Surplus 6,114 7,356 9,022 10,985 Total 6,248 7,490 9,156 11,119 Loan Funds Secured Loans 130 330 310 290 Unsecured Loans 168 150 30 30 Total 298 480 340 320 TOTAL 6,546 7,970 9,496 11,439 Application of Funds Fixed Assets Gross Block 1,396 1,736 2,136 2,636 Less: Depreciation 429 700 1,000 1,358 Net Block 967 1,036 1,136 1,278 Capital Work-in Progress 3 3 3 3 Investments 932 932 932 932 Current Assets, Loans and Advances Inventories 1,891 1,876 2,376 2,741 Sundry debtors 6,743 7,504 9,193 10,461 Cash and bank balances 1,247 1,253 1,618 2,690 Loans and advances 478 1,585 2,007 2,316 Total 10,359 12,217 15,194 18,208 Less: Current Liab. and Provisions Current Liabilities 5,878 6,376 7,908 9,106 Provisions 53 59 79 93 Total 5,932 6,435 7,986 9,199 Net Current Assets 4,427 5,782 7,208 9,009 Deferred Tax Asset (Net) 217 217 217 217 TOTAL 6,546 7,970 9,496 11,439 3

Cash Flow Statement A. Cash Flow from Operating Activities Profit after tax 1,749 1,917 2,573 3,034 Depreciation 256 271 300 358 Other adjustments 72 178 131 113 Working Capital changes (712) (1,349) (1,061) (729) Net Cash from Operating Activites 1,365 1,017 1,943 2,776 Direct Taxes paid (556) (651) (874) (1,031) Net Cash flow from Operation activities 810 366 1,069 1,746 B. Cash flow from Investing Activities: Capital Expenditure (179) (340) (400) (500) Investments 3 - - - Others (22) (0) (0) - Net Cash from Investing Activites (198) (340) (400) (500) C. Cash flow from Financing Activities Net borrowing (603) 182 (140) (20) Interest Payment ande Net divi & others (93) (202) (163) (154) Net Cash from Financing Activites (696) (20) (303) (174) Net Inc/(Dec) in Cash & Cash Equivalents (85) 6 366 1,072 Key Ratio Y/E Mar FY18 FY19E FY20E FY21E Valuation Matrix Price / Adj Earnings (x) 18.9 17.2 12.8 10.9 Price / CEPS (x) 15.4 14.2 10.9 9.2 Price / BV (x) 3.5 2.9 2.4 2.0 EV / EBIDTA (x) 9.5 9.2 7.0 5.7 EV / Sales (x) 1.3 1.2 0.9 0.7 EPS (Rs)-Adjusted 17.2 18.9 25.4 29.9 CEPS (Rs) 21.1 22.9 29.8 35.2 Book Value 93.3 111.8 136.7 166.0 Adj ROE (%) 20.4 18.4 20.4 19.8 ROCE (%) 31.0 27.9 30.0 29.1 Solvency Ratio (x) Total Debt / Equity (x) 0.05 0.06 0.04 0.03 Debt / EBIDTA 0.1 0.2 0.1 0.1 Debt / Capital Emp. 0.0 0.1 0.0 0.0 Capital Emp / Net Worth 1.0 1.1 1.0 1.0 Turnover Ratio (x) Asset Turnover Ratio 2.5 2.3 2.4 2.3 Fixed Asset Turnover Ratio 11.8 10.4 10.7 10.0 Working Capital Ratio (x) Current Ratio 1.7 1.9 1.9 2.0 Working Capital to Sales 0.3 0.3 0.3 0.3 Inventory (days) 42 38 38 38 Debtors (days) 149 152 147 145 Creditors (days) 130 129 126 126 Working Capital Cycle (Days) 61 61 59 57 4

Rating History Date Reco CMP TP 15-Feb-19 262 405 16-Nov-18 318 475 17-Aug-18 320 450 31-May-18 372 450 20-Feb-18 346 405 20-Nov-17 348 385 23-Aug-17 283 320 5-Jun-17 HOLD 330 320 PLEASE CLICK HERE FOR PREVIOUS REPORTS Rating Guides Rating Expected absolute returns (%) over 12 months >10% HOLD -5% to 10% REDUCE >-5% Reliance Securities Limited (RSL), the broking arm of Reliance Capital is one of the India s leading retail broking houses. Reliance Capital is amongst India s leading and most valuable financial services companies in the private sector. Reliance Capital has interests in asset management and mutual funds, life and general insurance, commercial finance, equities and commodities broking, wealth management services, distribution of financial products, private equity, asset reconstruction, proprietary investments and other activities in financial services. The list of associates of RSL is available on the website www.reliancecapital.co.in. RSL is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014 General Disclaimers: This Research Report (hereinafter called Report ) is prepared and distributed by RSL for information purposes only. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through RSL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security(ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by RSL to be reliable. RSL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of RSL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. Risks: Trading and investment in securities are subject to market risks. There are no assurances or guarantees that the objectives of any of trading / investment in securities will be achieved. The trades/ investments referred to herein may not be suitable to all categories of traders/investors. The names of securities mentioned herein do not in any manner indicate their prospects or returns. The value of securities referred to herein may be adversely affected by the performance or otherwise of the respective issuer companies, changes in the market conditions, micro and macro factors and forces affecting capital markets like interest rate risk, credit risk, liquidity risk and reinvestment risk. Derivative products may also be affected by various risks including but not limited to counter party risk, market risk, valuation risk, liquidity risk and other risks. Besides the price of the underlying asset, volatility, tenor and interest rates may affect the pricing of derivatives. Disclaimers in respect of jurisdiction: The possession, circulation and/or distribution of this Report may be restricted or regulated in certain jurisdictions by appropriate laws. No action has been or will be taken by RSL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. RSL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to RSL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India. Disclosure of Interest: The research analysts who have prepared this Report hereby certify that the views /opinions expressed in this Report are their personal independent views/opinions in respect of the securities and their respective issuers. None of RSL, research analysts, or their relatives had any known direct /indirect material conflict of interest including any long/short position(s) in any specific security on which views/opinions have been made in this Report, during its preparation. RSL s Associates may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report. RSL, its Associates, the research analysts, or their relatives might have financial interest in the issuer company(ies) of the said securities. RSL or its Associates may have received a compensation from the said issuer company(ies) in last 12 months for the brokerage or non brokerage services.rsl, its Associates, the research analysts or their relatives have not received any compensation or other benefits directly or indirectly from the said issuer company(ies) or any third party in last 12 months in any respect whatsoever for preparation of this report. The research analysts has served as an officer, director or employee of the said issuer company(ies)?: No RSL, its Associates, the research analysts or their relatives holds ownership of 1% or more, in respect of the said issuer company(ies).?: No Copyright: The copyright in this Report belongs exclusively to RSL. This Report shall only be read by those persons to whom it has been delivered. No reprinting, reproduction, copying, distribution of this Report in any manner whatsoever, in whole or in part, is permitted without the prior express written consent of RSL. RSL s activities were neither suspended nor have defaulted with any stock exchange with whom RSL is registered. Further, there does not exist any material adverse order/judgments/strictures assessed by any regulatory, government or public authority or agency or any law enforcing agency in last three years. Further, there does not exist any material enquiry of whatsoever nature instituted or pending against RSL as on the date of this Report. Important These disclaimers, risks and other disclosures must be read in conjunction with the information / opinions / views of which they form part of. RSL CIN: U65990MH2005PLC154052. SEBI registration no. ( Stock Brokers: NSE - INB / INF / INE 231234833; BSE - INB / INF / INE 011234839, Depository Participants: CDSL IN-DP-257-2016 IN-DP- NSDL-363-2013, Research Analyst: INH000002384); AMFI ARN No.29889. 5